Posted by Michael Wonder on 21 Feb 2026
Canada's public drug plans shouldn't cover new Alzheimer's drug, agency says
19 February 2026 - Lecanemab, also known as Leqembi, is approved to treat mild cognitive impairment, early Alzheimer's.
Public drug plans should not cover lecanemab, a drug to slow early-stage Alzheimer's disease, Canada's Drug Agency said Thursday in a draft recommendation.
